These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36096417)

  • 1. The Immunobiogram, a novel in vitro diagnostic test to measure the pharmacodynamic response to immunosuppressive therapy in kidney transplant patients.
    Pascual J; Jiménez C; Krajewska M; Seron D; Kotton CN; Portolés J; Witzke O; Sorensen SS; Andrés A; Crespo M; Paz-Artal E; Díez T; Ortega A; Portero I
    Transpl Immunol; 2022 Dec; 75():101711. PubMed ID: 36096417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
    Ulsh PJ; Yang HC; Holman MJ; Ahsan N
    J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The IMBG Test for Evaluating the Pharmacodynamic Response to Immunosuppressive Therapy in Kidney Transplant Patients: Current Evidence and Future Applications.
    Pascual J; Crespo M; Portoles J; Jimenez C; Ortega-Carrion A; Diez T; Portero I
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection.
    Theruvath TP; Saidman SL; Mauiyyedi S; Delmonico FL; Williams WW; Tolkoff-Rubin N; Collins AB; Colvin RB; Cosimi AB; Pascual M
    Transplantation; 2001 Jul; 72(1):77-83. PubMed ID: 11468538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection.
    Boratyńska M; Banasik M; Patrzałek D; Klinger M
    Ann Transplant; 2006; 11(2):51-6. PubMed ID: 17494290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
    Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.
    Su VCh; Greanya ED; Ensom MH
    Ann Pharmacother; 2011 Feb; 45(2):248-57. PubMed ID: 21304036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol biopsies in pediatric renal transplant recipients on cyclosporine versus tacrolimus-based immunosuppression.
    Aoun B; Decramer S; Vitkevic R; Wannous H; Bandin F; Azema C; Callard P; Brocheriou I; Ulinski T
    Pediatr Nephrol; 2013 Mar; 28(3):493-8. PubMed ID: 23111894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of immunosuppressive therapy in renal transplant recipients: an Italian observational study (the CESIT project).
    Rosa AC; Finocchietti M; Agabiti N; Menè P; Bracaccia ME; Bellini A; Massari M; Spila Alegiani S; Masiero L; Bedeschi G; Cardillo M; Lucenteforte E; Piccolo G; Leoni O; Ferroni E; Pierobon S; Nordio M; Ledda S; Garau D; Davoli M; Addis A; Belleudi V;
    BMC Nephrol; 2023 Oct; 24(1):320. PubMed ID: 37891504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Immunobiogram, a Novel
    Portoles JM; Jimenez C; Janeiro D; Lopez-Oliva MO; Ortega-Carrion A; Blanquez D; Arribas L; Gomez C; Diez T; Pascual J; Portero I
    Front Immunol; 2020; 11():618202. PubMed ID: 33569062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.
    Tsai SF; Cheng CY; Shu KH; Wu MJ
    Transplant Proc; 2012 Jan; 44(1):190-2. PubMed ID: 22310612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.